Maxim Group Believes BVNRY Still Has Room to Grow

By Jason Carr

In a report issued on March 13, Jason McCarthy from Maxim Group reiterated a Buy rating on Bavarian Nordic A/S (NASDAQ: BVNRY). The company’s shares closed yesterday at $15.50, equals to its 52-week high of $15.50.

According to, McCarthy is ranked 0 out of 5 stars with an average return of -10.5% and a 36.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Mateon Therapeutics Inc, and Stellar Biotechnologies.

Bavarian Nordic A/S has an analyst consensus of Moderate Buy.

The company has a one year high of $15.50 and a one year low of $10.44. Currently, Bavarian Nordic A/S has an average volume of 133.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company operates its business through the cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. It also develops and manufactures prophylactic vaccines, which include anthrax, human immunodeficiency virus, respiratory syncytial virus, and smallpox vaccines. The company was founded on July 1, 1992 and is headquartered in Kvistgaard, Denmark.